GlassScriptPhysician profile
Eun-Mi Yu
NPI 1093941114
$6,685.17
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,768 · 2020: $156 · 2021: $179 · 2022: $481 · 2023: $3,841 · 2024: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,594 · Food and Beverage: $489 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,594.00 |
| Food and Beverage | $488.68 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,459.32 | 2019-2023 | Lutathera |
| Astellas Pharma Global Development | $1,494.00 | 2023 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $524.53 | 2019-2024 | Opdivo |
| Seagen INC. | $366.35 | 2019-2023 | Padcev |
| Janssen Biotech, INC. | $331.01 | 2019-2024 | Erleada, Akeega |
| Merck Sharp & Dohme LLC | $263.38 | 2019-2024 | Welireg |
| Astellas Pharma US INC | $126.31 | 2019 | |
| Emd Serono, INC. | $120.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $111.84 | 2019 | |
| Taiho Oncology, INC. | $103.61 | 2019 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2022 | |
| Progenics Pharmaceuticals, INC. | $97.54 | 2022 | |
| Myovant Sciences INC. | $83.35 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $62.46 | 2019 | |
| Alexion Pharmaceuticals, INC. | $49.53 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $44.07 | 2019 | |
| Mylan Institutional INC. | $35.42 | 2019 | |
| Incyte Corporation | $34.98 | 2019 | |
| Exelixis INC. | $34.01 | 2019 | |
| Verastem, INC. | $30.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.10 | 2019 | |
| Medtronic USA, INC. | $22.46 | 2019 | |
| Daiichi Sankyo INC. | $19.92 | 2019 | |
| Agios Pharmaceuticals, INC. | $18.68 | 2019 | |
| Abbvie INC. | $17.68 | 2019 | |
| Pfizer INC. | $16.79 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.09 | 2019 | |
| Tersera Therapeutics LLC | $16.08 | 2019 | |
| Lilly USA, LLC | $15.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.11 | 2019 | |
| Genzyme Corporation | $13.31 | 2019 | |
| Dova Pharmaceuticals | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eun-Mi Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.